PTPN11 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL134958	0.53	10/20
SCHEMBL132945	0.51	10/20
Sipatrigine (SCHEMBL135888)	0.55	8/20
SCHEMBL39322	0.81	7/20
Lamotrigine (SCHEMBL35439)	0.53	7/20
SCHEMBL191746	0.37	7/20
SCHEMBL112985	0.68	6/20
SCHEMBL168816	0.68	6/20
SCHEMBL201318	0.54	5/20
SCHEMBL193772	0.50	5/20
SCHEMBL65166	0.37	5/20
SCHEMBL40166	0.59	4/20
SCHEMBL19707	0.54	4/20
SCHEMBL38951	0.54	4/20
SCHEMBL182309	0.53	4/20
SCHEMBL201493	0.53	4/20
SCHEMBL201612	0.53	4/20
SCHEMBL204373	0.53	4/20
SCHEMBL182147	0.48	4/20
SCHEMBL163996	0.43	4/20

Clinical trials — most relevant to PTPN11 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance	PHASE4	UNKNOWN
Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC	PHASE2/PHASE3	NOT_YET_RECRUITING
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease	PHASE2	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Immunoregulatory Therapy for 2019-nCoV	PHASE2	UNKNOWN
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer	PHASE2	RECRUITING
Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance	PHASE2	COMPLETED
Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase	PHASE2	COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	PHASE2	COMPLETED
A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma	PHASE2	UNKNOWN
Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer	PHASE2	UNKNOWN
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors	PHASE1	RECRUITING
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML	PHASE1	SUSPENDED
Palliative Thoracic Radiotherapy Plus BKM120	PHASE1	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing	nan	RECRUITING
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms	nan	NOT_YET_RECRUITING
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure	nan	UNKNOWN
Resistance to Immunotherapy in Gastric Cancer	nan	UNKNOWN
What is the Impact of TKI on Thyroid Function in CML Patients?	nan	NOT_YET_RECRUITING
rT3 and Inflammation in Hashimoto's Thyroiditis	nan	COMPLETED
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment	nan	NOT_YET_RECRUITING
JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders	nan	COMPLETED
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children	nan	NOT_YET_RECRUITING
Immune Signature of Palmoplantar Pustulosis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PTPN11 binder may also engage these)

Protein	Name	Similarity
P35235	—	1.000	P35235 →
P41499	—	1.000	P41499 →
Q90687	—	1.000	Q90687 →
P29351	—	1.000	P29351 →
PTPN6	Tyrosine-protein phosphatase non-receptor type 6	1.000	landscape →
P81718	—	0.994	P81718 →
Q03348	—	0.988	Q03348 →
PTPRA	Receptor-type tyrosine-protein phosphatase alpha	0.988	landscape →
Q5I142	—	0.986	Q5I142 →
F4IDQ6	—	0.985	F4IDQ6 →
Q64725	—	0.984	Q64725 →
O55082	—	0.983	O55082 →
G5EC24	—	0.983	G5EC24 →
P18052	—	0.983	P18052 →
Q8CIH5	—	0.983	Q8CIH5 →
BMX	Cytoplasmic tyrosine-protein kinase BMX	0.982	landscape →
Q00655	—	0.982	Q00655 →
Q9H1H9	—	0.982	Q9H1H9 →
P10686	—	0.982	P10686 →
Q5I141	—	0.982	Q5I141 →
PLCG1	1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1	0.982	landscape →
Q5I145	—	0.982	Q5I145 →
Q62077	—	0.982	Q62077 →
F4IJK6	—	0.981	F4IJK6 →
P43404	—	0.981	P43404 →
SYK	Tyrosine-protein kinase SYK	0.981	landscape →
Q5BJS0	—	0.981	Q5BJS0 →
O12990	—	0.981	O12990 →
O61722	—	0.981	O61722 →
P25044	—	0.981	P25044 →